Chemical Genetics and Orphan Genetic Diseases
Overview
Biology
Chemistry
Authors
Affiliations
Many orphan diseases have been identified that individually affect small numbers of patients but cumulatively affect approximately 6%-10% of the European and United States populations. Human genetics has become increasingly effective at identifying genetic defects underlying such orphan genetic diseases, but little progress has been made toward understanding the causal molecular pathologies and creating targeted therapies. Chemical genetics, positioned at the interface of chemistry and genetics, can be used for elucidation of molecular mechanisms underlying diseases and for drug discovery. This review discusses recent advances in chemical genetics and how small-molecule tools can be used to study and ultimately treat orphan genetic diseases. We focus here on a case study involving spinal muscular atrophy, a pediatric neurodegenerative disease caused by homozygous deletion of the SMN1 (survival of motor neuron 1) gene.
Validating therapeutic targets through human genetics.
Plenge R, Scolnick E, Altshuler D Nat Rev Drug Discov. 2013; 12(8):581-94.
PMID: 23868113 DOI: 10.1038/nrd4051.
Discovery, synthesis, and biological evaluation of novel SMN protein modulators.
Xiao J, Marugan J, Zheng W, Titus S, Southall N, Cherry J J Med Chem. 2011; 54(18):6215-33.
PMID: 21819082 PMC: 3174349. DOI: 10.1021/jm200497t.
Rossoll W, Bassell G Results Probl Cell Differ. 2009; 48:289-326.
PMID: 19343312 PMC: 3718852. DOI: 10.1007/400_2009_4.
Spinal muscular atrophy: advances in research and consensus on care of patients.
Wang C, Lunn M Curr Treat Options Neurol. 2008; 10(6):420-8.
PMID: 18990310 DOI: 10.1007/s11940-008-0044-7.
Inverse drug screens: a rapid and inexpensive method for implicating molecular targets.
Adams D, Levin M Genesis. 2006; 44(11):530-40.
PMID: 17078061 PMC: 3142945. DOI: 10.1002/dvg.20246.